(本文来自第一财经) 翔宇医疗发布异动公告称，近期资本市场对人脑工程、脑机接口等概念关注度较高，相关板块股价涨幅 较大。公司目前主要聚焦非侵入式脑机接口技术，覆盖作业疗法、运动疗法、认知言语、吞咽等康复全 场景布局，与当前国际上的侵入式脑机接口技术路线存在差异。公司在脑机接口方面的投入，目前在技 术、产品、渠道市场等方面形成一定的布局，但招投标和销售等具有滞后性，截至2025年末，相关产品 尚未实现规模化销售，营收占比较小。 ...

2连板翔宇医疗：目前主要聚焦非侵入式脑机接口技术，截至2025年末相关产品尚未实现规模化销售 2连板伟思医疗：在脑机接口领域的新产品仍处于市场培育初期，尚未实现规模化销售 2连板麦澜德：在脑机接口领域的产品尚处于研发及市场培育期，尚未实现规模化销售 ►暂不涉及脑机接口业务 ►脑机接口业务进展 2连板三博脑科：目前不涉及脑机接口产品的研发、生产及销售 2连板航天长峰：目前公司未实际开展脑机接口等相关业务、不从事商业航天相关业务 ...

Core Viewpoint - The company is focusing on expanding its business in the urology sector, particularly in the treatment of prostate diseases, which is expected to become a new growth point in the next 2-3 years [1][3]. Group 1: Business Performance - As of May 23, 2025, the company's stock price closed at 28.7 yuan, up 1.16% from the previous week, with a total market capitalization of 2.87 billion yuan [1]. - The company ranks 101 out of 126 in the medical device sector and 4226 out of 5148 in the A-share market [1]. Group 2: Product and Market Strategy - The decline in gross margin for the pelvic floor business is attributed to the initial low margins of new product promotions, but margins are expected to gradually recover as system solutions and combination sales strategies are implemented [1][3]. - The company is focusing on non-invasive brain-computer interface technology for neurodegenerative diseases, targeting conditions such as Alzheimer's and Parkinson's, with plans to expand application scenarios [1][3]. Group 3: Overseas Expansion - The short-term goal for overseas business is to deepen penetration in the Asia-Pacific market, while the long-term strategy shifts from "product output" to "demand-driven" approaches [2][3]. - The promotion of the Kangmei Center is still in its early stages, facing challenges such as medical insurance reimbursement limitations, while establishing model centers in Jiangsu and Zhejiang [2][3]. Group 4: Sales Strategy - The company employs a unique sales strategy that combines serious medical consumption with consumer medical seriousness, utilizing a tiered distribution model in serious medical markets and a multi-faceted marketing approach in consumer medical markets [2][3].

Group 1 - The core viewpoint of the article highlights that 麦澜德 is focusing on the male prostate disease market, which is expected to become a new growth point in the next 2-3 years [1] - 麦澜德's gross margin in the pelvic floor business has declined due to low margins from new product promotions, but it is anticipated to gradually recover and stabilize [1] - The company is concentrating on common scenarios such as stroke and neurological injury rehabilitation, with its pricing policy still in the improvement phase [1] Group 2 - 麦澜德 employs non-invasive brain-machine interface technology, targeting neurodegenerative diseases, strokes, and pediatric cerebral palsy, with plans to expand application scenarios in the future [1] - The short-term goal for overseas business is to deepen the Asia-Pacific market, while the medium to long-term goal shifts from "product output" to "demand-driven" [1] - Nearly half of the research and development investment is allocated to projects involving AI technology [1] Group 3 - The promotion of 康美中心 is still in its early stages, facing core challenges such as medical insurance pricing restrictions, insufficient market pricing mechanisms in hospitals, and consumer demand recognition [1] - The company adopts a tiered distribution model in the serious medical market and a multi-faceted marketing approach in the consumer medical market, emphasizing compliant promotion [1]